Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.53 |
| ▸ | CTSS | P25774 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | PRKX | P51817 | 1/20 | 0.47 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56596 | 1.00 | CTSK (0.53) | CTSKCTSSMAPTATMPRKACA | |
| SCHEMBL4353938 | 1.00 | CTSK (0.53) | CTSKCTSSMAPTATMPRKACA | |
| SCHEMBL21714668 | 0.92 | CTSK (0.51) | CTSKCTSSMAPTATMRIPK1 | |
| SCHEMBL4714695 | 0.92 | CTSK (0.51) | CTSKCTSSMAPTATMRIPK1 | |
| SCHEMBL14168716 | 0.89 | CTSK (0.51) | CTSKCTSSMAPTATMRIPK1 | |
| SCHEMBL4583120 | 0.88 | CTSK (0.53) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL4961187 | 0.88 | CTSK (0.56) | CTSKCTSSMAPTATMRIPK1 | |
| SCHEMBL28464584 | 0.88 | CTSK (0.53) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL127326 | 0.88 | RIPK1 (0.60) | CTSKCTSSMAPTATMRIPK1 | |
| SCHEMBL2481921 | 0.88 | RIPK1 (0.60) | CTSKCTSSMAPTATMRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110845369-B | Synthetic method of dapoxetine and intermediate thereof | 浙江工业大学 | 2022-03-18 | — | — | CN | claimed |
| CN-111018723-B | Preparation and detection method of dapoxetine hydrochloride isomer impurity | 盖天力医药控股集团制药股份有限公司 | 2022-03-08 | — | — | CN | claimed |
| CN-111018723-A | Preparation and detection method of dapoxetine hydrochloride isomer impurity | 盖天力医药控股集团制药股份有限公司 | 2020-04-17 | — | — | CN | claimed |
| CN-109790114-B | Novel chiral ligand, metal chelate, various unnatural amino acids and synthesis method of maraviroc and key intermediate thereof | 中国科学院上海药物研究所 | 2025-03-07 | — | — | CN | disclosed |
| US-20240409535-A1 | SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE | GENENTECH, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| US-20240317738-A1 | SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE | GENENTECH, INC. (US) | 2024-09-26 | — | — | US | disclosed |
| EP-4295845-A2 | SOLID FORMS OF THE TARTRATE SALT OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL, PROCESS FOR THEIR PREPARATION AND METHODS OF THEIR USE IN TREATING CANCERS | F. Hoffmann-La Roche AG (CH) | 2023-12-27 | — | — | EP | disclosed |
| US-11780834-B2 | Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3- yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use | GENENTECH, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| EP-3810283-B1 | SOLID FORMS OF THE TARTRATE SALT OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL, PROCESS FOR THEIR PREPARATION AND METHODS OF THEIR USE IN TREATING CANCERS | HOFFMANN LA ROCHE (CH) | 2023-06-14 | — | — | EP | disclosed |
| CN-110845369-B | Synthetic method of dapoxetine and intermediate thereof | 浙江工业大学 | 2022-03-18 | — | — | CN | disclosed |
| CN-110845369-B | Synthetic method of dapoxetine and intermediate thereof | 浙江工业大学 | 2022-03-18 | — | — | CN | disclosed |
| EP-1968940-A1 | 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| US-20070112022-A1 | Piperidine derivatives as ccr5 receptor modulators | ASTRAZENECA AB (SE) | 2007-05-17 | — | — | US | disclosed |
| EP-1654229-B1 | PIPERIDINE DERIVATIVES AS CCR5 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-05-09 | — | — | EP | disclosed |
| US-20060189650-A1 | Novel piperidine derivatives as modulators of chemokine receptor ccr5 | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| EP-1654229-A1 | PIPERIDINE DERIVATIVES AS CCR5 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2006-05-10 | — | — | EP | disclosed |
| EP-1572650-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005009959-A1 | PIPERIDINE DERIVATIVES AS CCR5 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | WO | disclosed |
| WO-2004056773-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112022-A1 | Piperidine derivatives as ccr5 receptor modulators | CCR5, CCR2, CCR6 | CTSK 4555/4885CTSS 3362/4885MAPT 4250/4885 |
| US-20060189650-A1 | Novel piperidine derivatives as modulators of chemokine receptor ccr5 | CCR5, CCR2, CCR1 | CTSK 3185/4885CTSS 2818/4885MAPT 3669/4885 |
| US-20240409535-A1 | SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE | TP53, DPYD, FLI1 | CTSK 4312/4885CTSS 4379/4885MAPT 3156/4885 |
| US-11780834-B2 | Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3- yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use | TP53, DPYD, FLI1 | CTSK 4312/4885CTSS 4379/4885MAPT 3156/4885 |
| US-20240317738-A1 | SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE | TP53, DPYD, FLI1 | CTSK 4312/4885CTSS 4379/4885MAPT 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.